Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV

Gene Therapy

Volumn 20, Issue 7, 2013, Pages 761-769

  Wang, P Y ^a,b   Currier, M A ^a,b   Hansford, L ^c   Kaplan, D ^c   Chiocca, E A ^d   Uchida, H ^e   Goins, W F ^e   Cohen, J B ^e   Glorioso, J C ^e   Van Kuppevelt, T H ^f   Mo, X ^b   Cripe, T P ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EBV LPD; HSV 1 entry receptors; oHSV

Indexed keywords

NECTIN 1;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOPROLIFERATIVE DISEASE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR XENOGRAFT; VIROTHERAPY; VIRUS ENTRY;

APOPTOSIS; CELL ADHESION MOLECULES; DNA, VIRAL; HERPESVIRUS 1, HUMAN; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PRIMARY CELL CULTURE; RECEPTORS, VIRUS;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 4; SIMPLEXVIRUS;

EID: 84880200078     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.93     Document Type: Article

References (39)

1. Jagadeesh D, Woda BA, Draper J, Evens AM. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122-136.
2. Martuza R. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000; 105: 841-846.
3. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94: 843-848.
4. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate hostcell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001; 3: 745-750.
5. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J 2002; 21: 954-965.
6. Warner MS, Geraghty RJ, Martinez WM, Montgomery RI, Whitbeck JC, Xu R et al. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 1998; 246: 179-189.
7. Lopez M, Cocchi F, Menotti L, Avitabile E, Dubreuil P, Campadelli-Fiume G. Nectin2alpha (PRR2alpha or HveB) and nectin2delta are low-efficiency mediators for entry of herpes simplex virus mutants carrying the Leu25Pro substitution in glycoprotein D. J Virol 2000; 74: 1267-1274.
8. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD et al. A novel role for 3-Osulfated heparan sulfate in herpes simplex virus entry. Cell 1999; 99: 13-22.
9. Krummenacher C, Baribaud F, Ponce de Leon M, Baribaud I, Whitbeck JC, Xu R et al. Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology 2004; 322: 286-299.
10. Huang YY, Yu Z, Lin SF, Li S, Fong Y, Wong RJ. Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 2007; 92: 1965-1970.
11. Yu Z, Adusumilli PS, Eisenberg DP, Darr E, Ghossein RA, Li S et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther 2007; 15: 103-113.
12. Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM et al. Engineered herpes simplex viruses efficiently infect and kill CD133 human glioma xenograft cells that express CD111. J Neurooncol 2009; 95: 199-209.
13. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007; 67: 11234-11243.
14. Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjolund J, Gisselsson D et al. HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106: 16805-16810.
15. Mohlin S, Pietras A, Wigerup C, Ora I, Andang M, Nilsson K et al. Tumor-initiating cells in childhood neuroblastoma-letter. Cancer Res 2012; 72: 821-822author reply 823.
16. Svachova H, Pour L, Sana J, Kovarova L, Raja KR, Hajek R. Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients. Leuk Res 2011; 35: 1008-1013.
17. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005; 65: 2832-2839.
18. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein and poliovirus receptor. Science 1998; 280: 1618-1620.
19. Uchida H, Chan J, Goins WF, Grandi P, Kumagai I, Cohen JB et al. A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type infection. J Virol 2010; 84: 12200-12209.
20. Uchida H, Shah WA, Ozuer A, Frampton Jr. AR, Goins WF, Grandi P et al. Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition. J Virol 2009; 83: 2951-2961.
21. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008.
22. Samanta M, Takada K. Modulation of innate immunity system by Epstein-Barr virus-encoded non-coding RNA and oncogenesis. Cancer Sci 2010; 101: 29-35.
23. Komano J, Maruo S, Kurozumi K, Oda T, Takada K. Oncogenic role of Epstein- Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 1999; 73: 9827-9831.
24. Swaminathan S, Huneycutt BS, Reiss CS, Kieff E. Epstein-Barr virus-encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes. J Virol 1992; 66: 5133-5136.
25. Ruf IK, Lackey KA, Warudkar S, Sample JT. Protection from interferon-induced apoptosis by Epstein-Barr virus small RNAs is not mediated by inhibition of PKR. J Virol 2005; 79: 14562-14569.
26. Bhat RATB. Two small RNAs encoded by Epstein-Barr virus can functionally substitute for the virus-associated RNAs in the lytic growth of adenovirus 5. Proc Natl Acad Sci USA 1983; 80: 4789-4793.
27. Bhat RA, Thimmappaya B. Construction and analysis of additional adenovirus substitution mutants confirm the complementation of VAI RNA function by two small RNAs encoded by Epstein-Barr virus. J Virol 1985; 56: 750-756.
28. Wang Y, Xue SA, Hallden G, Francis J, Yuan M, Griffin BE et al. Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res 2005; 65: 1523-1531.
29. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Martinelli G et al. PKR is activated in MDS patients and its subcellular localization depends on disease severity. Leukemia 2008; 22: 2267-2269.
30. Blalock WL, Bavelloni A, Piazzi M, Tagliavini F, Faenza I, Martelli AM et al. Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress. Leukemia 2011; 25: 236-245.
31. Rueger MA, Winkeler A, Miletic H, Kaestle C, Richter R, Schneider G et al. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene therapy 2005; 12: 588-596.
32. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879-3884.
33. Parikh N, Currier MA, Adams LC, Mahller YY, DiPasquale B, Collins MH et al. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 2005; 44: 469-478.
34. Choudhary S, Marquez M, Alencastro F, Spors F, Zhao Y, Tiwari V. Herpes simplex virus type-1 (HSV-1) entry into human mesenchymal stem cells is heavily dependent on heparan sulfate. J Biomed Biotechnol 2011; 2011: 264350.
35. Tiwari V, Clement C, Xu D, Valyi-Nagy T, Yue BY, Liu J et al. Role for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type entry into primary human corneal fibroblasts. J Virol 2006; 80: 8970-8980.
36. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16: 444-448.
37. Ten Dam GB, Kurup S, van de Westerlo EM, Versteeg EM, Lindahl U, Spillmann D et al. 3-O-sulfated oligosaccharide structures are recognized by antiheparan sulfate antibody HS4C3. J Biol Chem 2006; 281: 4654-4662.
38. Dulbecco R, Vogt M. Some problems of animal virology as studied by the plaque technique. Cold Spring Harbour Symp Quant Biol 1953; 18: 273-279.
39. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.